Floatz logo

Ambroxol

Gaucher Disease, Type 1

Shaare Zedek Medical CenterSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Gaucher Disease, Type 1 cohort.

Asset / SponsorPhaseRating
Velaglucerase Alfa
Shaare Zedek Medical Center
Phase 4A
Cerezyme
Genzyme, a Sanofi Company
Phase 4A
Eliglustat
Genzyme, a Sanofi Company
Phase 3BBB
ISOFAGOMINE
Amicus Therapeutics
Phase 2BB
isu302
ISU Abxis Co., Ltd.
Phase 3BB

View all 11 →

Same molecule, other indications

Ambroxol is also rated in:

Parkinson diseaseDormant
BB
Indicative ·
65 / 100
View asset →
GBA1-related Parkinson disease, susceptibilityDormant
BB
Indicative ·
64 / 100
View asset →
mucus inspissation of respiratory tractDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →